---
schema_version: "secwatch.filing_event.v1"
accession: "0001295947-24-000015"
form_type: "8-K"
ticker: "PBH"
cik: "0001295947"
company_name: "Prestige Consumer Healthcare Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:23:18.218305+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Prestige Consumer Q4 revenue down 2.9%; adj. EPS $1.02; $300M buyback; FY2025 EPS guidance $4.40-$4.46

## Summary
- Q4 revenue $277.0M (-2.9% ex-FX); non-GAAP adj. diluted EPS $1.02 vs $1.07 prior year.
- Full-year FY2024 revenue $1,125.4M (flat); GAAP diluted EPS $4.17; non-GAAP diluted EPS $4.21.
- Leverage ratio improved to 2.8x, below 3x target; net debt ~$1.1B.
- Board authorized new $300M share repurchase program; timing subject to market conditions.
- Initial FY2025 guidance: organic revenue growth ~1%, diluted EPS $4.40-$4.46, free cash flow $240M+.

## SEC filing metadata
- accession: 0001295947-24-000015
- form_type: 8-K
- ticker: PBH
- cik: 0001295947
- company_name: Prestige Consumer Healthcare Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1295947/000129594724000015/0001295947-24-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1295947/000129594724000015/pbh-20240514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001295947-24-000015
- JSON: https://secwatch.observer/filing/0001295947-24-000015.json
- Plain text: https://secwatch.observer/filing/0001295947-24-000015.txt

## Key facts
- Earnings Releases
  Prestige Consumer Healthcare Inc. reported the fiscal quarter ended March 31, 2024 results: revenue $277.0 million, net income $49.5 million, EPS $0.98. Guidance initiated.
  - Period: the fiscal quarter ended March 31, 2024
  - Revenue: $277.0 million
  - Net income: $49.5 million
  - EPS: $0.98
  - Guidance: initiated
  - Result: reported results
  source text: Reported revenues in the fourth quarter of fiscal 2024 of $277.0 million compared to $285.9 million in the fourth quarter of fiscal 2023. Revenues decreased 2.9% excluding the impact of foreign currency. The revenue decline in the quarter was attributable to the inability to supply customer orders late in the quarter in certain brands, the strategic exit of private label revenues, and a lower Women’s Health category, partially offset by growth in the International OTC segment. Reported net income for the fourth quarter of fiscal 2024 was $49.5 million versus the prior year comparable quarter’s net loss of $240.6 million. Diluted earnings per share of $0.98 for the fourth quarter of fiscal 2024 compared to a $4.83 diluted loss per share in the prior year comparable period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1295947/000129594724000015/0001295947-24-000015-index.htm
- Earnings Releases
  Prestige Consumer Healthcare Inc. reported the fiscal year ended March 31, 2024 results: revenue $1,125.4 million, net income $209.3 million, EPS $4.17. Guidance initiated.
  - Period: the fiscal year ended March 31, 2024
  - Revenue: $1,125.4 million
  - Net income: $209.3 million
  - EPS: $4.17
  - Guidance: initiated
  - Result: reported results
  source text: Reported revenues for the fiscal year 2024 totaled $1,125.4 million compared to revenues of $1,127.7 million for the fiscal year 2023. Revenues increased 0.2% excluding the impact of foreign currency. Revenue performance for the fiscal year was driven by strong International OTC segment performance and strong Eye & Ear Care, GI, and Dermatological category sales in North America, partially offset by lower Women’s Health, Cough & Cold, and Analgesic category sales and the strategic exit of private label revenues. Reported net income for fiscal 2024 of $209.3 million compared to the prior year comparable period net loss of $82.3 million. Reported Fiscal 2024 diluted earnings per share was $4.17, compared to diluted loss per share of $1.65 in the prior year comparable period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1295947/000129594724000015/0001295947-24-000015-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.